Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23931424 | 0.75 | MIF (0.37) | MIFHCAR2P2RY6CYP11B1CYP11B2 | |
| SCHEMBL19666544 | 0.75 | MIF (0.37) | MIFHCAR2P2RY6CYP11B1CYP11B2 | |
| SCHEMBL1020699 | 0.75 | MIF (0.44) | MIFP2RY6 | |
| SCHEMBL20663282 | 0.71 | — | — | |
| SCHEMBL23539895 | 0.71 | CYP11B1 (0.36) | MIFP2RY6CYP11B1CYP11B2 | |
| SCHEMBL30317587 | 0.71 | CYP11B1 (0.36) | MIFP2RY6CYP11B1CYP11B2 | |
| SCHEMBL30298644 | 0.68 | MIF (0.54) | MIFP2RY6 | |
| SCHEMBL20337 | 0.68 | MIF (0.54) | MIFP2RY6 | |
| SCHEMBL24538276 | 0.68 | MIF (0.34) | MIFP2RY6 | |
| SCHEMBL24225 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | UCB Biopharma SRL (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4081295-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4081295-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-114980975-A | Dihydrocyclopentaisoquinoline sulfonamide derivatives | UCB生物制药有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | MIF 905/4885HCAR2 49/4885P2RY6 281/4885 |
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | HRH2, HRH4, HRH1 | MIF 1885/4885HCAR2 30/4885P2RY6 315/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | MIF 2764/4885HCAR2 5/4885P2RY6 581/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MIF 2764/4885HCAR2 5/4885P2RY6 581/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MIF 1146/4885HCAR2 2645/4885P2RY6 887/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MIF 1146/4885HCAR2 2645/4885P2RY6 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.